NASDAQ:XENE - Xenon Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$5.50 -0.05 (-0.90 %)
(As of 05/25/2018 02:37 PM ET)
Previous Close$5.50
Today's Range$5.35 - $5.55
52-Week Range$2.10 - $7.00
Volume6,473 shs
Average Volume177,335 shs
Market Capitalization$79.36 million
P/E Ratio-3.20
Dividend YieldN/A
Beta0.72

About Xenon Pharmaceuticals (NASDAQ:XENE)

Xenon Pharmaceuticals logoXenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. The company uses Extreme Genetics, a core enabling discovery platform for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies. It clinical development pipeline includes XEN1101, a Kv7 potassium channel opener for the treatment of epilepsy comprising treatment-resistant adult and pediatric focal seizures, rare and pediatric forms of epilepsy, and other neurological disorders; and XEN901, a selective Nav1.6 sodium channel inhibitor for the treatment of epilepsy. The company also develops GDC-0310 that completed Phase I clinical trials for the treatment of pain; and XEN007, a central nervous system (CNS)-acting calcium channel blocker that directly modulates Cav2.1, which is a critical calcium channel implicated in the pathophysiology of hemiplegic migraine, a rare and debilitating neurological disorder. Xenon Pharmaceuticals Inc. has collaboration agreements with Genentech, Inc. and Merck & Co., Inc. The company was founded in 1996 and is headquartered in Burnaby, Canada.

Receive XENE News and Ratings via Email

Sign-up to receive the latest news and ratings for XENE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:XENE
CUSIPN/A
Phone604-484-3300

Debt

Debt-to-Equity Ratio0.82
Current Ratio9.70
Quick Ratio9.70

Price-To-Earnings

Trailing P/E Ratio-3.20
Forward P/E Ratio-3.72
P/E GrowthN/A

Sales & Book Value

Annual Sales$310,000.00
Price / Sales251.40
Cash FlowN/A
Price / CashN/A
Book Value$0.47 per share
Price / Book11.70

Profitability

EPS (Most Recent Fiscal Year)($1.72)
Net Income$-30,700,000.00
Net Margins-9,872.67%
Return on Equity-79.04%
Return on Assets-58.43%

Miscellaneous

Employees81
Outstanding Shares14,170,000

Xenon Pharmaceuticals (NASDAQ:XENE) Frequently Asked Questions

What is Xenon Pharmaceuticals' stock symbol?

Xenon Pharmaceuticals trades on the NASDAQ under the ticker symbol "XENE."

How were Xenon Pharmaceuticals' earnings last quarter?

Xenon Pharmaceuticals Inc (NASDAQ:XENE) announced its quarterly earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.48) by $0.27. Xenon Pharmaceuticals had a negative net margin of 9,872.67% and a negative return on equity of 79.04%. View Xenon Pharmaceuticals' Earnings History.

When is Xenon Pharmaceuticals' next earnings date?

Xenon Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for Xenon Pharmaceuticals.

What price target have analysts set for XENE?

3 analysts have issued twelve-month price targets for Xenon Pharmaceuticals' stock. Their predictions range from $5.00 to $9.00. On average, they anticipate Xenon Pharmaceuticals' stock price to reach $6.6667 in the next year. View Analyst Ratings for Xenon Pharmaceuticals.

Who are some of Xenon Pharmaceuticals' key competitors?

Who are Xenon Pharmaceuticals' key executives?

Xenon Pharmaceuticals' management team includes the folowing people:
  • Dr. Simon N. Pimstone, CEO & Director (Age 50)
  • Mr. Ian C. Mortimer, Pres, CFO, COO & Company Sec. (Age 42)
  • Mr. Robin P. Sherrington, Exec. VP of Bus. & Corp. Devel. (Age 57)
  • Dr. Y. Paul Goldberg, Sr. VP of Clinical Devel. (Age 58)
  • Dr. James R. Empfield Ph.D., Sr. VP of Drug Discovery of Xenon Pharmaceuticals USA Inc (Age 57)

Has Xenon Pharmaceuticals been receiving favorable news coverage?

News coverage about XENE stock has trended somewhat positive on Friday, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Xenon Pharmaceuticals earned a media sentiment score of 0.09 on Accern's scale. They also gave media stories about the biopharmaceutical company an impact score of 45.20 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

Who are Xenon Pharmaceuticals' major shareholders?

Xenon Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include BVF Inc. IL (5.09%), Nexthera Capital LP (2.68%), Knott David M (0.81%) and Sabby Management LLC (0.47%). Company insiders that own Xenon Pharmaceuticals stock include Bvf Partners L P/Il, Frank A Holler, Gary Patou, Ian Mortimer, James R Empfield, Michael R Hayden, Mohammad Azab, Raymond Winquist, Richard H Scheller, Simon N Pimstone, Steven Gannon and Value Fund L P Biotechnology. View Institutional Ownership Trends for Xenon Pharmaceuticals.

Which institutional investors are selling Xenon Pharmaceuticals stock?

XENE stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL and Sabby Management LLC. View Insider Buying and Selling for Xenon Pharmaceuticals.

Which institutional investors are buying Xenon Pharmaceuticals stock?

XENE stock was acquired by a variety of institutional investors in the last quarter, including Nexthera Capital LP and Knott David M. Company insiders that have bought Xenon Pharmaceuticals stock in the last two years include Bvf Partners L P/Il, Gary Patou, Ian Mortimer, James R Empfield, Michael R Hayden, Mohammad Azab, Raymond Winquist, Richard H Scheller, Simon N Pimstone, Steven Gannon and Value Fund L P Biotechnology. View Insider Buying and Selling for Xenon Pharmaceuticals.

How do I buy shares of Xenon Pharmaceuticals?

Shares of XENE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Xenon Pharmaceuticals' stock price today?

One share of XENE stock can currently be purchased for approximately $5.45.

How big of a company is Xenon Pharmaceuticals?

Xenon Pharmaceuticals has a market capitalization of $79.36 million and generates $310,000.00 in revenue each year. The biopharmaceutical company earns $-30,700,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis. Xenon Pharmaceuticals employs 81 workers across the globe.

How can I contact Xenon Pharmaceuticals?

Xenon Pharmaceuticals' mailing address is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. The biopharmaceutical company can be reached via phone at 604-484-3300 or via email at [email protected]


MarketBeat Community Rating for Xenon Pharmaceuticals (XENE)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  161 (Vote Outperform)
Underperform Votes:  110 (Vote Underperform)
Total Votes:  271
MarketBeat's community ratings are surveys of what our community members think about Xenon Pharmaceuticals and other stocks. Vote "Outperform" if you believe XENE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XENE will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Xenon Pharmaceuticals (NASDAQ:XENE) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Xenon Pharmaceuticals in the last 12 months. Their average twelve-month price target is $6.6667, suggesting that the stock has a possible upside of 21.21%. The high price target for XENE is $9.00 and the low price target for XENE is $5.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.6667$6.6667$5.00$8.1667
Price Target Upside: 21.21% upside36.05% upside66.67% upside172.22% upside

Xenon Pharmaceuticals (NASDAQ:XENE) Consensus Price Target History

Price Target History for Xenon Pharmaceuticals (NASDAQ:XENE)

Xenon Pharmaceuticals (NASDAQ:XENE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/22/2018Jefferies GroupBoost Price TargetBuy$6.00MediumView Rating Details
3/8/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$7.00 ➝ $9.00HighView Rating Details
6/27/2017Canaccord GenuityReiterated RatingBuy$5.00LowView Rating Details
12/22/2016Bloom BurtonInitiated CoverageBuy$14.50N/AView Rating Details
9/26/2016GuggenheimInitiated CoverageBuy ➝ Buy$20.00N/AView Rating Details
(Data available from 5/25/2016 forward)

Earnings

Xenon Pharmaceuticals (NASDAQ:XENE) Earnings History and Estimates Chart

Earnings by Quarter for Xenon Pharmaceuticals (NASDAQ:XENE)

Xenon Pharmaceuticals (NASDAQ:XENE) Earnings Estimates

2018 EPS Consensus Estimate: ($1.96)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.49)($0.49)($0.49)
Q2 20181($0.49)($0.49)($0.49)
Q3 20181($0.47)($0.47)($0.47)
Q4 20181($0.51)($0.51)($0.51)

Xenon Pharmaceuticals (NASDAQ XENE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/1/2018($0.49)N/AView Earnings Details
5/8/20183/31/2018($0.48)($0.21)$0.10 millionViewN/AView Earnings Details
3/7/2018After Market($0.11)($0.45)$6.38 million$0.02 millionViewListenView Earnings Details
11/7/2017Q3 2017($0.08)($0.43)$6.52 million$0.26 millionViewN/AView Earnings Details
8/3/20176/30/2017($0.38)($0.41)$0.38 million$0.02 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.35)($0.43)$0.45 million$0.02 millionViewN/AView Earnings Details
3/8/201712/31/2016($0.42)($0.32)$0.40 million$0.38 millionViewListenView Earnings Details
11/3/2016Q316($0.43)($0.51)$0.40 million$0.41 millionViewListenView Earnings Details
8/3/2016Q216($0.48)($0.42)$0.50 million$0.41 millionViewN/AView Earnings Details
5/10/2016Q116($0.21)($0.23)$3.30 million$0.60 millionViewListenView Earnings Details
3/8/2016Q415($0.16)($0.27)$4.90 million$3.23 millionViewListenView Earnings Details
11/10/2015Q315($0.02)($0.27)$4.65 million$4.29 millionViewListenView Earnings Details
8/10/2015Q215($0.16)($0.07)$4.90 million$4.05 millionViewListenView Earnings Details
5/12/2015Q115$0.14($0.30)$4.65 million$4.00 millionViewListenView Earnings Details
3/12/2015Q4($0.09)$1.57$5.10 million$4.43 millionViewListenView Earnings Details
12/15/2014$0.41$1.69$5.00 million$13.19 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Xenon Pharmaceuticals (NASDAQ:XENE) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Xenon Pharmaceuticals (NASDAQ XENE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 14.13%
Institutional Ownership Percentage: 44.82%
Insider Trading History for Xenon Pharmaceuticals (NASDAQ:XENE)
Institutional Ownership by Quarter for Xenon Pharmaceuticals (NASDAQ:XENE)

Xenon Pharmaceuticals (NASDAQ XENE) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/15/2017Mohammad AzabDirectorBuy15,000$2.22$33,300.00View SEC Filing  
9/22/2017Mohammad AzabDirectorBuy10,000$2.95$29,500.0021,210View SEC Filing  
8/18/2017Mohammad AzabDirectorBuy6,335$2.90$18,371.5012,898View SEC Filing  
8/18/2017Raymond WinquistInsiderBuy1,000$3.00$3,000.001,000View SEC Filing  
8/15/2017Bvf Partners L P/IlMajor ShareholderBuy18,858$2.41$45,447.78View SEC Filing  
8/15/2017James R EmpfieldSVPBuy10,000$2.48$24,800.0010,000View SEC Filing  
8/15/2017Value Fund L P BiotechnologyInsiderBuy60,202$2.61$157,127.22View SEC Filing  
8/14/2017Bvf Partners L P/IlMajor ShareholderBuy41,344$2.70$111,628.80View SEC Filing  
8/14/2017Michael R HaydenDirectorBuy15,000$2.75$41,250.00161,187View SEC Filing  
8/11/2017Steven GannonDirectorBuy15,000$2.82$42,300.0015,000View SEC Filing  
8/10/2017Ian MortimerCFOBuy15,000$2.88$43,200.006,000View SEC Filing  
8/10/2017Richard H SchellerDirectorBuy7,000$2.85$19,950.007,000View SEC Filing  
8/10/2017Simon N PimstoneCEOBuy6,000$2.90$17,400.00217,847View SEC Filing  
8/8/2017Gary PatouDirectorBuy5,000$3.00$15,000.0012,028View SEC Filing  
6/27/2017Value Fund L P BiotechnologyInsiderBuy85,461$4.00$341,844.00View SEC Filing  
6/22/2017Value Fund L P BiotechnologyInsiderBuy20,411$4.00$81,644.00View SEC Filing  
6/19/2017Value Fund L P BiotechnologyInsiderBuy26,408$3.84$101,406.72View SEC Filing  
6/7/2017Value Fund L P BiotechnologyInsiderBuy358,698$3.81$1,366,639.38View SEC Filing  
12/15/2016Frank A HollerDirectorSell30,000$7.85$235,500.00115,869View SEC Filing  
8/19/2016Frank A HollerDirectorSell11,938$7.65$91,325.70145,869View SEC Filing  
8/18/2016Frank A HollerDirectorSell18,062$7.93$143,231.66169,006View SEC Filing  
6/24/2016Ian MortimerCFOBuy5,300$6.22$32,966.001,000View SEC Filing  
9/24/2015Y. Paul GoldbergVPSell22,149$8.88$196,683.126,000View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Xenon Pharmaceuticals (NASDAQ XENE) News Headlines

Source:
DateHeadline
Xenon Pharmaceuticals Inc. (XENE) Expected to Post Quarterly Sales of $60,000.00Xenon Pharmaceuticals Inc. (XENE) Expected to Post Quarterly Sales of $60,000.00
www.americanbankingnews.com - May 19 at 3:56 AM
-$0.49 Earnings Per Share Expected for Xenon Pharmaceuticals Inc. (XENE) This Quarter-$0.49 Earnings Per Share Expected for Xenon Pharmaceuticals Inc. (XENE) This Quarter
www.americanbankingnews.com - May 17 at 10:36 AM
Blog Exposure - Xenon Announced Presentation of Positive XEN1101 TMS Pharmacodynamic Phase-1 Data at 14th Eilat ConferenceBlog Exposure - Xenon Announced Presentation of Positive XEN1101 TMS Pharmacodynamic Phase-1 Data at 14th Eilat Conference
finance.yahoo.com - May 17 at 8:24 AM
Xenon Pharma (XENE) Presents XEN1101 Interim Phase 1 Data At 14th Eilat Conference - SlideshowXenon Pharma (XENE) Presents XEN1101 Interim Phase 1 Data At 14th Eilat Conference - Slideshow
seekingalpha.com - May 16 at 5:40 PM
Are Xenon Pharmaceuticals Shares Making a Run?Are Xenon Pharmaceuticals Shares Making a Run?
www.msn.com - May 15 at 5:48 PM
Xenon Pharmaceuticals to Host Conference Call and Webcast to Provide Corporate Update and OverviewXenon Pharmaceuticals to Host Conference Call and Webcast to Provide Corporate Update and Overview
www.nasdaq.com - May 15 at 8:29 AM
Xenon Pharma up 21% premarket on positive XEN1101 dataXenon Pharma up 21% premarket on positive XEN1101 data
seekingalpha.com - May 15 at 8:29 AM
Xenon Presents XEN901 Phase 1 Clinical Update and Supporting Pre-clinical Data at 14th Eilat ConferenceXenon Presents XEN901 Phase 1 Clinical Update and Supporting Pre-clinical Data at 14th Eilat Conference
feeds.benzinga.com - May 15 at 6:39 AM
Xenon Pharmaceuticals to Host Conference Call and Webcast to Provide Corporate Update and Overview of ...Xenon Pharmaceuticals to Host Conference Call and Webcast to Provide Corporate Update and Overview of ...
globenewswire.com - May 14 at 5:19 PM
Xenon Pharmaceuticals to Host Conference Call and Webcast to Provide Corporate Update and Overview of XEN1101 and XEN901 Presentations at 14th Eilat ConferenceXenon Pharmaceuticals to Host Conference Call and Webcast to Provide Corporate Update and Overview of XEN1101 and XEN901 Presentations at 14th Eilat Conference
finance.yahoo.com - May 14 at 5:19 PM
Xenon Pharmaceuticals Inc. Expected to Earn Q2 2018 Earnings of ($0.49) Per Share (XENE)Xenon Pharmaceuticals Inc. Expected to Earn Q2 2018 Earnings of ($0.49) Per Share (XENE)
www.americanbankingnews.com - May 14 at 1:17 AM
Xenon Pharmaceuticals (XENE) CEO Simon Pimstone on Q1 2018 Results - Earnings Call TranscriptXenon Pharmaceuticals' (XENE) CEO Simon Pimstone on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 12 at 5:52 PM
Xenon Pharmaceuticals (XENE) Rating Increased to Buy at Zacks Investment ResearchXenon Pharmaceuticals (XENE) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - May 10 at 3:23 PM
Edited Transcript of XENE earnings conference call or presentation 8-May-18 8:30pm GMTEdited Transcript of XENE earnings conference call or presentation 8-May-18 8:30pm GMT
finance.yahoo.com - May 10 at 8:26 AM
Xenon Pharmaceuticals (XENE) Issues Quarterly  Earnings ResultsXenon Pharmaceuticals (XENE) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 9 at 1:58 PM
Xenon Pharmaceuticals: 1Q Earnings SnapshotXenon Pharmaceuticals: 1Q Earnings Snapshot
finance.yahoo.com - May 9 at 8:20 AM
Xenon Pharma beats by $0.27Xenon Pharma beats by $0.27
seekingalpha.com - May 8 at 5:38 PM
Xenon Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate UpdateXenon Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - May 8 at 5:38 PM
Xenon Pharmaceuticals (XENE) Upgraded by ValuEngine to "Buy"Xenon Pharmaceuticals (XENE) Upgraded by ValuEngine to "Buy"
www.americanbankingnews.com - May 2 at 1:37 PM
Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2018 Financial Results and Provide Corporate UpdateXenon Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2018 Financial Results and Provide Corporate Update
finance.yahoo.com - May 1 at 5:17 PM
Xenon Pharmaceuticals Inc. (XENE) Expected to Announce Quarterly Sales of $100,000.00Xenon Pharmaceuticals Inc. (XENE) Expected to Announce Quarterly Sales of $100,000.00
www.americanbankingnews.com - May 1 at 2:02 AM
Xenon Pharmaceuticals (XENE) to Release Earnings on MondayXenon Pharmaceuticals (XENE) to Release Earnings on Monday
www.americanbankingnews.com - April 30 at 8:55 AM
Xenon Pharmaceuticals Inc. (XENE) Expected to Post Earnings of -$0.48 Per ShareXenon Pharmaceuticals Inc. (XENE) Expected to Post Earnings of -$0.48 Per Share
www.americanbankingnews.com - April 29 at 9:06 PM
Xenon Pharmaceuticals to Present at the 2018 Bloom Burton & Co. Healthcare Investor ConferenceXenon Pharmaceuticals to Present at the 2018 Bloom Burton & Co. Healthcare Investor Conference
finance.yahoo.com - April 25 at 5:28 PM
Xenon Pharmaceuticals (XENE) Receives "Buy" Rating from Canaccord GenuityXenon Pharmaceuticals (XENE) Receives "Buy" Rating from Canaccord Genuity
www.americanbankingnews.com - April 20 at 3:00 PM
 Analysts Anticipate Xenon Pharmaceuticals Inc. (XENE) Will Post Quarterly Sales of $100,000.00 Analysts Anticipate Xenon Pharmaceuticals Inc. (XENE) Will Post Quarterly Sales of $100,000.00
www.americanbankingnews.com - April 14 at 1:49 AM
Xenon Pharmaceuticals (XENE) Lifted to "Hold" at ValuEngineXenon Pharmaceuticals (XENE) Lifted to "Hold" at ValuEngine
www.americanbankingnews.com - April 2 at 10:26 PM
Xenon Pharmaceuticals Confirms Closing of Transaction with Teva and Announces Preferred Share Exchange ...Xenon Pharmaceuticals Confirms Closing of Transaction with Teva and Announces Preferred Share Exchange ...
globenewswire.com - March 30 at 5:29 PM
Xenon Pharmaceuticals Confirms Closing of Transaction with Teva and Announces Preferred Share Exchange Agreement with BVF Partners L.P.Xenon Pharmaceuticals Confirms Closing of Transaction with Teva and Announces Preferred Share Exchange Agreement with BVF Partners L.P.
finance.yahoo.com - March 28 at 5:17 PM
Zacks: Analysts Anticipate Xenon Pharmaceuticals Inc (XENE) Will Announce Earnings of -$0.48 Per ShareZacks: Analysts Anticipate Xenon Pharmaceuticals Inc (XENE) Will Announce Earnings of -$0.48 Per Share
www.americanbankingnews.com - March 26 at 11:08 PM
Jefferies Group Raises Xenon Pharmaceuticals (XENE) Price Target to $6.00Jefferies Group Raises Xenon Pharmaceuticals (XENE) Price Target to $6.00
www.americanbankingnews.com - March 22 at 3:02 PM
Dr. Ernesto Aycardi Joins Xenon Pharmaceuticals as Chief Medical Officer - GlobeNewswire (press release)Dr. Ernesto Aycardi Joins Xenon Pharmaceuticals as Chief Medical Officer - GlobeNewswire (press release)
globenewswire.com - March 14 at 8:35 AM
Xenon Pharmaceuticals (XENE) Names Dr. Ernesto Aycardi as Chief Medical OfficerXenon Pharmaceuticals (XENE) Names Dr. Ernesto Aycardi as Chief Medical Officer
www.streetinsider.com - March 13 at 7:15 PM
Dr. Ernesto Aycardi Joins Xenon Pharmaceuticals as Chief Medical OfficerDr. Ernesto Aycardi Joins Xenon Pharmaceuticals as Chief Medical Officer
finance.yahoo.com - March 13 at 7:15 PM
Xenon Pharmaceuticals Inc (XENE) Forecasted to Earn Q1 2018 Earnings of ($0.49) Per ShareXenon Pharmaceuticals Inc (XENE) Forecasted to Earn Q1 2018 Earnings of ($0.49) Per Share
www.americanbankingnews.com - March 12 at 1:17 AM
Xenon Pharmaceuticals (XENE) Downgraded by ValuEngine to SellXenon Pharmaceuticals (XENE) Downgraded by ValuEngine to Sell
www.americanbankingnews.com - March 11 at 7:10 PM
Stifel Nicolaus Increases Xenon Pharmaceuticals (XENE) Price Target to $9.00Stifel Nicolaus Increases Xenon Pharmaceuticals (XENE) Price Target to $9.00
www.americanbankingnews.com - March 11 at 10:28 AM
Zacks: Brokerages Expect Xenon Pharmaceuticals Inc (XENE) to Announce -$0.47 Earnings Per ShareZacks: Brokerages Expect Xenon Pharmaceuticals Inc (XENE) to Announce -$0.47 Earnings Per Share
www.americanbankingnews.com - March 9 at 5:18 PM
Xenon Pharmaceuticals Reports 2017 Financial Results and Provides Corporate Update - GlobeNewswire (press release)Xenon Pharmaceuticals Reports 2017 Financial Results and Provides Corporate Update - GlobeNewswire (press release)
globenewswire.com - March 9 at 8:21 AM
Xenon Pharmaceuticals (XENE) Releases  Earnings ResultsXenon Pharmaceuticals (XENE) Releases Earnings Results
www.americanbankingnews.com - March 8 at 10:29 AM
Xenon Pharmaceuticals Reports 2017 Financial Results and Provides Corporate UpdateXenon Pharmaceuticals Reports 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - March 7 at 6:33 PM
Xenon Pharmaceuticals Inc. to Host Earnings CallXenon Pharmaceuticals Inc. to Host Earnings Call
finance.yahoo.com - March 7 at 6:33 PM
Xenon Pharmaceuticals Q4 Earnings OutlookXenon Pharmaceuticals Q4 Earnings Outlook
finance.yahoo.com - March 7 at 6:33 PM
Xenon Pharmaceuticals (XENE) Rating Increased to Hold at ValuEngineXenon Pharmaceuticals (XENE) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - March 1 at 11:30 PM
Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss 2017 Financial Results and Provide Corporate UpdateXenon Pharmaceuticals to Host Conference Call and Webcast to Discuss 2017 Financial Results and Provide Corporate Update
finance.yahoo.com - February 28 at 6:02 PM
Xenon Pharmaceuticals (XENE) Raised to "Hold" at Zacks Investment ResearchXenon Pharmaceuticals (XENE) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - February 28 at 3:45 PM
Xenon Pharmaceuticals (XENE) Set to Announce Earnings on TuesdayXenon Pharmaceuticals (XENE) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - February 27 at 2:34 AM
Xenon Pharmaceuticals Inc (XENE) Expected to Post Quarterly Sales of $6.38 MillionXenon Pharmaceuticals Inc (XENE) Expected to Post Quarterly Sales of $6.38 Million
www.americanbankingnews.com - February 22 at 4:32 AM
-$0.11 EPS Expected for Xenon Pharmaceuticals Inc (XENE) This Quarter-$0.11 EPS Expected for Xenon Pharmaceuticals Inc (XENE) This Quarter
www.americanbankingnews.com - February 20 at 11:14 PM
BRIEF-Xenon Advances Second Proprietary Epilepsy Product Into Clinic With Initiation Of Xen901 Phase 1 Clinical TrialBRIEF-Xenon Advances Second Proprietary Epilepsy Product Into Clinic With Initiation Of Xen901 Phase 1 Clinical Trial
www.reuters.com - February 20 at 5:45 PM

SEC Filings

Xenon Pharmaceuticals (NASDAQ:XENE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Xenon Pharmaceuticals (NASDAQ:XENE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Xenon Pharmaceuticals (NASDAQ XENE) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.